OLYMY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 14.38% compared to Olympus's net margin of -107.23%. Olympus's return on equity of 4.7% beat Healios KK's return on equity of -137.21%.

Olympus has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus has higher upside potential than Healios KK, analysts believe Olympus is more attractive than Healios KK.

Olympus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Olympus has a quarterly dividend of $0.12 per share corresponding to a yield of 0.79%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus pays 8.27% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Olympus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Olympus quarterly revenues are $1.6B, which are larger than Healios KK quarterly revenues of $3.2M. Olympus's net income of $231.6M is higher than Healios KK's net income of -$3.4M. Notably, Olympus's price-to-earnings ratio is 63.90x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus is 2.64x versus 22.75x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 14.38% compared to Olympus's net margin of -5.57%. Olympus's return on equity of 4.7% beat PeptiDream's return on equity of 34.66%.

Olympus has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus has higher upside potential than PeptiDream, analysts believe Olympus is more attractive than PeptiDream.

Olympus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.804, suggesting its less volatile than the S&P 500 by 19.554%.

Olympus has a quarterly dividend of $0.12 per share corresponding to a yield of 0.79%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus pays 8.27% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Olympus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Olympus quarterly revenues are $1.6B, which are larger than PeptiDream quarterly revenues of $36.8M. Olympus's net income of $231.6M is higher than PeptiDream's net income of -$2.1M. Notably, Olympus's price-to-earnings ratio is 63.90x while PeptiDream's PE ratio is 21.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus is 2.64x versus 7.43x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 14.38% compared to Olympus's net margin of 12.96%. Olympus's return on equity of 4.7% beat Nxera Pharma's return on equity of -5.58%.

Olympus has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus has higher upside potential than Nxera Pharma, analysts believe Olympus is more attractive than Nxera Pharma.

Olympus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.86%.

Olympus has a quarterly dividend of $0.12 per share corresponding to a yield of 0.79%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus pays 8.27% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Olympus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Olympus quarterly revenues are $1.6B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Olympus's net income of $231.6M is higher than Nxera Pharma's net income of $8.1M. Notably, Olympus's price-to-earnings ratio is 63.90x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus is 2.64x versus 2.95x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 14.38% compared to Olympus's net margin of 7.83%. Olympus's return on equity of 4.7% beat Takeda Pharmaceutical's return on equity of 4.01%.

Olympus has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $15.66 which suggests that it could grow by 20.94%. Given that Takeda Pharmaceutical has higher upside potential than Olympus, analysts believe Takeda Pharmaceutical is more attractive than Olympus.

Olympus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.642%.

Olympus has a quarterly dividend of $0.12 per share corresponding to a yield of 0.79%. Takeda Pharmaceutical offers a yield of 4.78% to investors and pays a quarterly dividend of $0.33 per share. Olympus pays 8.27% of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend. Olympus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Olympus quarterly revenues are $1.6B, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Olympus's net income of $231.6M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Olympus's price-to-earnings ratio is 63.90x while Takeda Pharmaceutical's PE ratio is 21.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus is 2.64x versus 1.37x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.